Bridge Biotherapeuticsincis A Clinical Stage Biotechnology Company Founded In 2015 And Headquartered In South Koreawith Additional Labs And Offices In The U Sthe Company Is Dedicated To Developing Innovative Therapeutics For Diseases With Significant Unmet Medical Needssuch As Cancersfibrotic Diseasesand Ulcerative Colitisthe Company S Clinical Pipeline Includes Bbt 401A Pellino 1 Inhibitor For Ulcerative Colitis In Phase Ii Trialsbbt 877An Autotaxin Inhibitor For Fibrotic Diseases Like Idiopathic Pulmonary Fibrosisand Bbt 176A Targeted Therapy For Non Small Cell Lung Cancer Patients With Specific Egfr Mutationsbridge Biotherapeutics Emphasizes Drug Discovery And Developmentleveraging Its Expertise In Structural Biology And Translational Research To Address Complex Medical Challengesthe Company Actively Seeks Partnerships To Advance Its Unlicensed Products And Collaborates Globally To Enhance Its Clinical Programs
